• About us
    • Who we are
    • Our strategy
    • How we are funded
    • Our people
    • Governance and structure
    • Reports and statements
    • Our impact
    • Suppliers
  • Our strategy
    • Our strategy
    • Neurodegeneration
    • Respiratory health
  • Working with us
    • Support for MRC researchers
    • Helping charities
    • Our partners
    • Available technologies
    • Advise & Connect: Covid-19
  • Funding
    • LifeArc Ventures
    • Rare disease research funding
    • Development Gap Fund
    • Current funding opportunities
  • Capabilities
    • Drug discovery
    • Antibody humanisation
    • IP management and technology transfer
    • Diagnostics development
  • Careers
    • Working at LifeArc
    • Our culture
    • Benefits and rewards
    • Students and fellows
    • How to apply
    • Job vacancies
  • News
    • Latest news
    • Case studies
    • Reports and publications
    • Newsletter

A selection of our portfolio

About
Our ventures team
Portfolio companies
News
Contact

Our companies

AviadoBio
AviadoBio
AviadoBio

Developing transformative medicines for patients living with debilitating and life-threatening neurodegenerative disorders

Find out more
Caldan Therapeutics
Caldan Therapeutics
Caldan Therapeutics

Developing activators of free fatty acid receptors to treat metabolic diseases, including type 2 diabetes and non-alcoholic steatohepatitis (NASH)

Find out more
Closed Loop Medicines
Closed Loop Medicines
Closed Loop Medicines

Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians

Find out more
Cumulus Neuroscience 
Cumulus Neuroscience 
Cumulus Neuroscience 

Their next-generation integrated physiological and digital biomarker platform can monitor diseases of the central nervous system at home – providing feedback on disease progression and response to treatment

Find out more
Eliem Therapeutics, Inc (NASDAQ: ELYM)
Eliem Therapeutics, Inc (NASDAQ: ELYM)
Eliem Therapeutics, Inc (NASDAQ: ELYM)

Developing ETX-810 to treat chronic pain, and ETX-155, to treat major depressive disorder, perimenopausal depression and focal onset seizures. LifeArc invested alongside RA Capital, Intermediate Capital Group, Access Biotechnology, Samlyn Capital and Acorn Bioventures in a $60 million Series B financing in May 2021.

Find out more
Ikarovec
Ikarovec
Ikarovec

Developing novel, differentiated gene therapies for eye conditions, including diabetic macular oedema, age-related macular degeneration (AMD) and intra-ocular hypertension

Find out more
Pheno Therapeutics 
Pheno Therapeutics 
Pheno Therapeutics 

Discovering and developing small molecules to promote remyelination to treat multiple sclerosis

Find out more
Surgery Hero
Surgery Hero
Surgery Hero

Surgery Hero is a virtual program that helps people prepare their mind and body for surgery through sustainable lifestyle changes.

Find out more
Quick links
  • Newsletter
  • Privacy policy
  • Cookie policy
  • Modern slavery statement
  • Sitemap
  • Contact us
Follow us
Get in touch
Lynton House
7-12 Tavistock Square
London WC1H 9LT UK

+44 (0)20 7391 2700
LifeArc is a charity registered with the Charity Commission for England and Wales no. 1015243 and a charity registered in Scotland with the Office of the Scottish Charity Regulator no. SC037861. LifeArc is a company limited by guarantee no. 2698321 incorporated in England and Wales. | © LifeArc 2023
Web design by TWK